Market Alert: Trump Revives Trade War Playbook with Tariff Threats
Anatara Lifesciences Ltd (ASX: ANR) has been granted a standard patent in Hong Kong for its flagship GaRP product, “Gastrointestinal Health Composition,” further strengthening its global intellectual property position. The patent (HK 40078260), effective from 9 October 2020, protects until 9 October 2040. This development follows earlier grants of similar patents in Europe and Australia, reinforcing GaRP’s potential as a disease-modifying solution for gastrointestinal disorders.
GaRP targets the unmet needs in conditions such as irritable bowel syndrome (IBS) by supporting the gastrointestinal lining and microbiome balance. With a non-prescription market opportunity estimated at US$8 billion (AU$ 12.2 billion) in the US alone, Anatara’s expanding patent coverage is crucial for commercialization efforts. The company is also exploring further jurisdictional protections, building momentum from its recently completed GaRP-IBS Phase II trial.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
